AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
Lipocalin 13 Recombinant, Antibody & ELISA Kits
A Secreted Protein Enhances Insulin Sensitivity
Lipocalin (LCN) family members are small secreted proteins that bind to small hydrophobic molecules via their characteristic central -barrels. A couple of LCN family members, including major urinary protein 1, retinol-binding protein 4, LCN2, and LCN13, have been reported to regulate insulin sensitivity and nutrient metabolism. LCN13 is expressed by multiple tissues, including the liver, pancreas, epididymis, and skeletal muscle, and is secreted into the bloodstream in mice. Obesity is associated with a downregulation of LCN13 expression and lower levels of circulating LCN13. LCN13 therapies overcome LCN13 deficiency in mice with either genetic or dietary obesity, leading to an improvement in hyperglycemia, hyperinsulinemia, insulin resistance, glucose intolerance, and hepatic steatosis. In hepatocytes, LCN13 directly suppresses hepatic gluconeogenesis and lipogenesis but increases fatty acid oxidation. LCN13 also enhances insulin sensitivity in adipocytes. The potential mechanisms of the antidiabetes and antisteatosis actions of LCN13 are discussed.
Obesity is associated with hepatic steatosis, partially due to increased lipogenesis and decreased fatty acid -oxidation in the liver; however, the underlying mechanism of abnormal lipid metabolism is not fully understood. We reported previously that obesity is associated with LCN13 (lipocalin 13) deficiency. LCN13 is a lipocalin family member involved in glucose metabolism, and LCN13 deficiency appears to contribute to hyperglycemia in obese mice. Here, we show that LCN13 is also an important regulator of lipogenesis and beta-oxidation in the liver. In primary hepatocytes, recombinant LCN13 directly suppressed lipogenesis and increased fatty acid -oxidation, whereas neutralization of endogenous LCN13 had an opposite effect. Transgenic overexpression of LCN13 protected against hepatic steatosis in mice with either dietary or genetic (ob/ob) obesity. LCN13 transgenic overexpression also improved hyperglycemia, glucose intolerance, and insulin resistance in ob/ob mice. Short-term LCN13 overexpression via an adenovirus-mediated gene transfer similarly attenuated hepatic steatosis in db/db mice. LCN13 inhibited the expression of important lipogenic genes and stimulated the genes that promote -oxidation. These results suggest that LCN13 decreases liver lipid levels by both inhibiting hepatic lipogenesis and stimulating -oxidation. LCN13 deficiency is likely to contribute to fatty liver disease in obese mice.

mouse lipocalin-13 elisa kit sk00648-01

Mouse Lipocalin 13 ELISA Kit
Code No.: SK00648-01
Size: 96 T
Price: $460.00 USD
Standard Range: 312-20000 pg/ml
Sensitivity: 100 pg/ml
Sepecificity: Mouse Lipocalin 13 at 100%; rat and bovine serum samples indicated crossreaction with this elisa kit
Protein ID:NP_705786
Gene ID: NM_153558
Intra-CV: 4-8 %
Inter-CV: 8-12%
Protocol: PDF

 

Mouse Lipocalin 13 Recombinant
Code No.: 00648-01-100
Size: 100 ug
Price: $360.00 USD
Protein ID:NP_705786
Gene ID: NM_153558
MW: 21.3 KD
Tag: His Tag on N-Terminus
Expressed: E. Coli
Purity: 95%
Data Sheet: PDF
Rabbit Anti Lipocalin-13 IgG
Code No.: A00593-01-100
Size: 100 ug
Price: $260.00 USD
Host:Rabbit
Antigen: Mouse Lipocalin-13 rec
Ab Type: Polyclonal IgG
Purification: Protein A
Applications: E, IHC, WB
Working Dilution: 2-4 ug/ml)
Data Sheet: PDF

 

Name
Code No.
Size
Price ($)
Lipocalin 13 (Mouse) ELISA Kit
96 T
460.00
Lipocalin 13 (Mouse) rec
100 ug
360.00
Lipocalin 13 (Mouse) rec Biotinylated
50 ug
360.00
Lipocalin 13 (Mouse) rec Cy3 Conjugated
50 ug
450.00
Rabbit Anti Lipocalin 13 (Mouse) Antibody
100 ug
260.00
Anti Lipocalin-13 (Mouse) IgG Biotinylated
50 ug
360.00